Searchable abstracts of presentations at key conferences in endocrinology

ea0056p1176 | Thyroid cancer | ECE2018

131I-MIBG as a treatment in medullary thyroid carcinoma with distant metastases.

Uriarte Nerea Utrilla , Fernandez Pedro Gonzalez , Figueruelo Alba Esteban , Herrero Marina Nevares , Sandi Javier Santamaria

Introduction and objectives: The strategies for therapy of metastatic medullary thyroid carcinoma (MTC) are limited. Although Tyrosine kinase inhibitors (TKI) seem to be the first-line treatment, we want to explore other possibilities. Metaiodobenzylguanidine (MIBG) is a guanethidine derivative, structurally similar to norepinephrine. It was developed as an imaging agent with 123I radiolabeling. MIBG localizes neuroendocrine tumors including MTC. We are investigatin...

ea0090ep723 | Pituitary and Neuroendocrinology | ECE2023

Cure rates after different therapy lines among patients with growth hormone (GH)-secreting pituitary adenomas

Moure Maria Dolores , Ortiz Elizabeth Salinas , Del Diego Maria Munoz , Estella Elena Gonzalez , Arauco Claudia Sanchez , Sandi Javier Santamaria

Introduction: Even Though resection via transsphenoidal surgery is the optimal primary treatment for growth hormone (GH) secreting pituitary adenomas, medical therapy must also be considered when biochemical control after surgery is not achieved. The aim of our study was to describe the cure rates of acromegaly patients after different lines of therapy.Methods: A retrospective study (1971–2022) of 89 patients diagnosed with acromegaly was conducted....